Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED

Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

41 42 Next >

Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial

September 26, 2023

From Cybin Inc.

Via Business Wire

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Cantor Global Healthcare Conference

September 25, 2023

Via Investor Brand Network

Cybin to Participate in the Cantor Global Healthcare Conference

September 25, 2023

From Cybin Inc.

Via Business Wire

What 11 Analyst Ratings Have To Say About Cybin ↗

September 01, 2023

Via Benzinga

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting

September 22, 2023

Via Investor Brand Network

Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression ↗

September 21, 2023

Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive...

Via Benzinga

Cybin Announces Date of Annual and Special Meeting of Shareholders

September 21, 2023

From Cybin Inc.

Via Business Wire

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Enrollment in Phase 2 CYB003 Study

September 21, 2023

Via Investor Brand Network

Topics Intellectual Property

Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

September 21, 2023

From Cybin Inc.

Via Business Wire

Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

September 20, 2023

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death Intellectual Property

Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗

September 20, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday.

Via Benzinga

Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket ↗

September 19, 2023

Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 73.5% to $0.1313 in pre-market trading after falling 15% on Monday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 19, 2023

Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning!

Via InvestorPlace

Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update ↗

September 18, 2023

Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).

Via Benzinga

The 3 Most Undervalued Under-$1 Stocks to Buy in September 2023 ↗

September 14, 2023

Cheap valuations and prospects for future growth should get individual investors excited for these under-$1 stocks to buy.

Via InvestorPlace

NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years ↗

September 12, 2023

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

Via Benzinga

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT ↗

September 05, 2023

The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and...

Via Benzinga

Topics Intellectual Property

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗

September 05, 2023

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

Via Benzinga

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notification of Approval for U.S. Patent Covering Deuterated Tryptamines

September 05, 2023

Via Investor Brand Network

Topics Intellectual Property

Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines

September 05, 2023

From Cybin Inc.

Via Business Wire

Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions ↗

August 31, 2023

Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka...

Via Benzinga

Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M ↗

August 29, 2023

Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9...

Via Benzinga

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗

August 28, 2023

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

Via Benzinga

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety ↗

August 28, 2023

Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o

Via Benzinga

Cybin to Acquire Small Pharma Inc.

August 28, 2023

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for...

Via Newsfile

Topics Intellectual Property

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’

August 28, 2023

Via Investor Brand Network

Topics Intellectual Property

Cybin to Acquire Small Pharma Inc.

August 28, 2023

From Cybin Inc.

Via Business Wire

Funding The Future Of Psychedelics: Cybin Launches Renewed ATM Equity Program Up To $35M ↗

August 24, 2023

Psychedelics biotech Cybin Inc. (NYSE: CYBN) announced it has renewed its previously established at-the-market (ATM) equity program allowing the company to gradually issue and sell up to $35 million...

Via Benzinga

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Renewed ATM Program of up to US$35M

August 24, 2023

Via Investor Brand Network

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.